Arbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of ($0.21), $0.02 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $2.11 million versus the consensus estimate of $3.31 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.